您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 英国药房
产地国家: 英国
所属类别: 作用于呼吸系统药物->呼吸道感染
处方药:处方药
包装规格: 100毫克/2毫升 每包5个
计价单位:
  点击放大  
生产厂家英文名:
Bristol Myers Squib UK
该药品相关信息网址1:
https://www.rxlist.com/amikacin-sulfate-injection-drug.htm
原产地英文商品名:
AMIKIN PAED AMP 100MG/2ML Pack of 5
原产地英文药品名:
AMIKACIN SULFATE
中文参考商品译名:
AMIKIN PAED AMP 100毫克/2毫升 每包5个
中文参考药品译名:
阿米卡星硫酸盐
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Bacterial sepsis
英文适应病症2:
Severe infection of the respiratory tract
临床试验期:
完成
中文适应病症参考翻译1:
细菌性败血症
中文适应病症参考翻译2:
严重感染呼吸道
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20194317191513.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
 部分中文AMIKIN PAED处方资料(仅供参考)


【英文名称】
AMIKIN PAED

【适用证】

阿米卡星硫酸盐注射液适用于由革兰氏阴性菌敏感菌株引起的严重感染的短期治疗,包括假单胞菌属,大肠杆菌,吲哚阳性和吲哚阴性变形杆菌属,普罗威登斯菌种,克雷伯氏菌属。肠杆菌属 - 沙雷氏菌属物种和不动杆菌属(Mima-Herellea)物种。

临床研究表明,阿米卡星硫酸盐注射液可有效治疗细菌性败血症(包括新生儿败血症);严重感染呼吸道,骨骼和关节,中枢神经系统(包括脑膜炎)和皮肤和软组织;腹腔感染(包括腹膜炎);以及烧伤和术后感染(包括血管外手术)。临床研究表明阿米卡星对由于这些生物引起的严重复杂和复发性尿路感染也有效。包括阿米卡星硫酸盐注射液在内的氨基糖苷类药物并未在尿路感染的简单初始发作中表明,除非致病微生物对易受毒性较小的抗生素不敏感。

应进行细菌学研究以确定致病微生物及其对阿米卡星的敏感性。阿米卡星可被认为是疑似革兰氏阴性感染的初始治疗,可在获得药敏试验结果之前进行治疗。临床试验表明,阿米卡星对由革兰阴性生物的庆大霉素和/或妥布霉素抗性菌株引起的感染是有效的,特别是变形虫,普罗威登斯氏菌,粘质沙雷氏菌和铜绿假单胞菌。继续使用该药物治疗的决定应基于药敏试验的结果,感染的严重程度,患者的反应和 上面“警告”框中包含的重要附加注意事项。

阿米卡星也被证明对葡萄球菌感染有效,并且可以在某些条件下被认为是治疗已知或疑似葡萄球菌疾病的初始治疗,例如致病生物体可能是革兰氏阴性细菌的严重感染。或葡萄球菌,对其他抗生素过敏的患者中的葡萄球菌敏感菌株感染,以及混合葡萄球菌/革兰氏阴性感染。

在某些严重感染如新生儿败血症中,可能需要同时使用青霉素类药物进行治疗,因为可能会因革兰氏阳性菌如链球菌或肺炎球菌而感染。

为了减少耐药细菌的发展并保持阿米卡星和其他抗菌药物的有效性,阿米卡星应仅用于治疗或预防已被证实或强烈怀疑由易感细菌引起的感染。当获得培养和易感性信息时,应在选择或修改抗菌疗法时考虑这些信息。在缺乏此类数据的情况下,当地流行病学和易感性模式可能有助于经验性选择治疗。

【用法用量】

应获得患者的预处理体重以计算正确的剂量。 阿米卡星硫酸盐注射液可以肌内或静脉内给药。

应通过测量血清肌酐浓度或计算内源性肌酐清除率来估计肾功能状态。 为此目的,血尿素氮(BUN)的可靠性要低得多。 治疗期间应定期重新评估肾功能。

应尽可能测量血清中阿米卡星浓度,以确保足够但不过量。 期望在治疗期间间歇地测量峰值和谷值血清浓度。 应避免峰值浓度(注射后30至90分钟)高于35微克/ mL和低于10微克/毫升的谷浓度(恰好在下一次剂量之前)。

应根据指示调整剂量。

【禁忌】

对阿米卡星过敏的病史是其使用的禁忌症。 由于已知患者对该类药物的交叉敏感性,对氨基糖甙类药物过敏或严重毒性反应的病史可能禁止使用任何其他氨基糖苷类药物。

【Therapeutic indications】

Amikacin Sulfate Injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter (Mima-Herellea) species.

Clinical studies have shown Amikacin Sulfate Injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. Aminoglycosides, including Amikacin Sulfate Injection are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity.

Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin- and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri, Providencia stuartii, Serratia marcescens, and Pseudomonas aeruginosa. The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above.

Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections.

In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
 

【CONTRAINDICATIONS】

A history of hypersensitivity to amikacin is a contraindication for its use. A history of hypersensitivity or serious toxic reactions to aminoglycosides may contraindicate the use of any other aminoglycoside because of the known cross-sensitivities of patients to drugs in this class.
 

【DOSAGE AND ADMINISTRATION】

The patient’s pretreatment body weight should be obtained for calculation of correct dosage. Amikacin Sulfate Injection may be given intramuscularly or intravenously.

The status of renal function should be estimated by measurement of the serum creatinine concentration or calculation of the endogenous creatinine clearance rate. The blood urea nitrogen (BUN) is much less reliable for this purpose. Reassessment of renal function should be made periodically during therapy.

Whenever possible, amikacin concentrations in serum should be measured to assure adequate but not excessive levels. It is desirable to measure both peak and trough serum concentrations intermittently during therapy. Peak concentrations (30 to 90 minutes after injection) above 35 micrograms per mL and trough concentrations (just prior to the next dose) above 10 micrograms per mL should be avoided.

Dosage should be adjusted as indicated.
 

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(20194317191513.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2019-4-2
附件:
20194317191513.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com